Bioventus (BVS) Cash from Operations Growth (1y) (2021 - 2026)
Bioventus (BVS) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.80 Bn | 176.50 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.84 Bn | 125.96 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.59 Bn | 99.37 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.51 Bn | 67.06 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.18 Bn | 44.51 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.16 Bn | 25.88 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.66 Bn | 21.54 Bn | 2.07 Bn | 122.43% |
| 10 | Bioventus | 825.73 Mn | 789.88 Mn | 90.77 Mn | 146.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 146.22% |
| Dec 31, 2025 | 96.50% |
| Sep 27, 2025 | 191.76% |
| Jun 28, 2025 | 71.07% |
| Mar 29, 2025 | -221.92% |
| Dec 31, 2024 | 86.25% |
| Sep 28, 2024 | 198.40% |
| Jun 29, 2024 | 40.45% |
| Mar 30, 2024 | -228.89% |
| Dec 31, 2023 | 136.58% |
| Sep 30, 2023 | -6,735.44% |
| Jul 1, 2023 | 267.30% |
| Apr 1, 2023 | 122.17% |
| Dec 31, 2022 | -66.57% |
| Oct 1, 2022 | -98.51% |
| Jul 2, 2022 | -83.04% |
| Apr 2, 2022 | -16.50% |
| Dec 31, 2021 | -48.45% |
| Oct 2, 2021 | -49.20% |
| Jul 3, 2021 | 121.60% |